Our Perspective

Gen Re has just completed our 16th annual U.S. Critical Illness Market Survey. The data gathered from 53 participating carriers captures a moment-in-time snapshot of where the market is today. This snapshot comes to life when we look to the historical...

Medicine is changing - but what that means to patients and insurers could mean very different things. Even within our world of insurance, the answer will vary by product. Will rapid advancements in cancer diagnosis and treatment mean greater profits...

Millions have benefitted from the cushion Critical Illness (CI) products provide to financial hardship linked to a cancer diagnosis, stroke or heart attack. CI has also been rewarding for providers, not just by helping them remain relevant but by also...

A consensus among medical experts is that histopathology will lose its importance in selecting appropriate cancer treatment, and eventually diagnosis, over the course of the next 15 years. During this time, liquid biopsy techniques targeted at finding...

Almost one in four cases of female breast cancer diagnoses around the world are in the Asia-Pacific region – the highest proportion of new cases in China (46%), Japan (14%) and Indonesia (12%). The global total of new cancer cases is projected...

The fundamental aim of lump sum Dread Disease insurance is to help meet the costs associated with the treatment of a critical illness such as a heart attack or cancer. The claims money may also enable the policyholder to take time off work whilst recovering,...